

Glucocorticosteroids administration is associated with increased regulatory T cells in equine asthmatic lungs

Roxane Boivin, Amandine Vargas, Patricia Cano, Jean-Pierre Lavoie*

Department of Clinical Sciences, Faculty of Veterinary Medicine, Université de Montréal, 3200, rue Sicotte, Saint-Hyacinthe, Quebec, J2S 2M2, Canada

ARTICLE INFO

Keywords:

Glucocorticosteroid
Regulatory T cell
Asthma
Lung

ABSTRACT

Recurrent inflammation in severe equine asthma causes a remodeling of the airways leading to incompletely reversible airway obstruction. Despite the improvement of clinical signs and lung function with glucocorticoids (GC), inflammation, translated by an increased percentage of neutrophils, persists in the airways. Regulatory T cells (Treg) have been shown to have anti-inflammatory properties and play an important role in balancing the immune response by suppressing effector lymphocyte activity. However, interactions between Treg, neutrophils and glucocorticosteroids *in vivo* are unclear, particularly in asthma. Furthermore, the effects of GC on Treg in the airway of asthmatic horses have not been investigated. We hypothesized that horses with severe asthma display a decreased population of pulmonary Treg when compared to healthy controls, and that treatment with GC lead to an increased pulmonary Treg cell population only in affected horses. Using lung function measurements and flow cytometry with surface antigens CD4 and FoxP3, we investigated Treg in airway luminal cells obtained by bronchoalveolar lavage fluid (BALF) from 6 asthmatic horses in exacerbation of the disease and 6 aged-match controls, kept in the same environment, before and following a 2-week treatment with dexamethasone. Results showed that the number of Treg increases only in the lungs of asthmatic horses following GC therapy, despite continued presence of increased numbers of neutrophils. Our results support the complexity of the interaction between Treg, neutrophils and GC.

1. Introduction

Severe equine asthma (heaves, recurrent airway obstruction) is characterized by a recurrent airway obstruction and a chronic neutrophilic airway inflammation (Leclerc et al., 2011). The condition is exacerbated by exposures to barn antigens, particularly those present in hay. However, the immune process contributing to the airway inflammation remains ill-defined, and different cell populations, including T cells, appears to play a role in the development and perpetuation of inflammation in equine and human asthma, notably by release of pro-inflammatory cytokines such as IL-1 β , IL-4, IL-23 and IL-17 (Robinson et al., 2004; Lloyd and Hawrylowicz, 2009; Voo et al., 2009). Severe asthmatic horses often display Th2 and Th17 responses, which in human is associated with increased airway inflammation (Broide and Firestein, 1991; Robinson et al., 1996; Debrue et al., 2005; Ainsworth et al., 2006; Choy et al., 2015). Th17 cells are of a particular interest, as they promote the recruitment of neutrophils by producing IL-17 to further intensify chronic inflammation (Pelletier et al., 2010).

It is known that recurrent inflammation in equine asthma causes a remodeling of the airways, which in turn, leads to severe airway obstruction, and the incurability of the condition (Leclerc et al., 2011).

Interestingly, healthy horses also develop airway inflammation when exposed to stable antigens, but without developing lung diseases (Tremblay et al., 1993; Ivester et al., 2014). In these animals, inflammation is generally transient, while it persists in asthmatic horses. These findings suggest that appropriate autoregulation is possibly lacking in the lungs of affected horses and contribute to the persistent inflammation. Regulatory T cells (Treg) have anti-inflammatory properties by suppressing effector lymphocyte activity and therefore play an important role in balancing the immune response in asthma (Kearley et al., 2005; Lewkowich et al., 2005; Kearley et al., 2008). Forkhead box transcription factor FoxP3 is a critical regulator of Treg development and function and its expression is required for T cell immunosuppressor activities (Fontenot et al., 2003; Hori et al., 2003). Treg exert these effects by direct contact with the effector cells and also by the production of anti-inflammatory molecules, including IL-10 and TGF- β .

Abbreviations: BALF, bronchoalveolar lavage fluid; FoxP3, forkhead box protein 3 transcription factor; GC, glucocorticosteroid; GILZ, glucocorticoid-induced leucine zipper; P_L, transpulmonary pressure; Treg, regulatory T cell

* Corresponding author at: Faculty of Veterinary Medicine, Université de Montréal, 3200, rue Sicotte, Saint-Hyacinthe, Quebec, J2S 2M2, Canada.

E-mail addresses: roxane.boivin@umontreal.ca (R. Boivin), amandine.vargas@umontreal.ca (A. Vargas), Patricia.Cano@ac-toulouse.fr (P. Cano), jean-pierre.lavoie@umontreal.ca (J.-P. Lavoie).

<https://doi.org/10.1016/j.vetimm.2018.05.010>

Received 22 January 2018; Received in revised form 17 April 2018; Accepted 22 May 2018
0165-2427/ © 2018 Elsevier B.V. All rights reserved.

Treg and Th17 cells share common differentiation pathways, and microenvironment changes can induce plasticity of these T cell phenotypes (Sehrawat and Rouse, 2017). It has been suggested that the balance between Treg and Th17 cells activities contributes to numerous infectious and non-infectious diseases (Sehrawat and Rouse, 2017).

The production of IL-10 and TGF- β by neutrophils is increased in presence of LPS-activated Treg (Lewkowicz et al., 2013). As the stabling environment of horses is rich in endotoxins (Riihimäki et al., 2008; Elfman et al., 2009; Whittaker et al., 2009), this may represent an additional means by which Treg contribute to homeostasis in healthy horses by dampening inflammation. However, because of its pro-fibrotic properties, Treg could conversely contribute to airway remodeling and to the deposition of collagen observed in equine asthma (Setlakwe et al., 2014; MacDonald et al., 2015). Studies have also shown that neutrophils can modulate recruitment of Th17 and Treg, and that T cells can induce the recruitment, activation and persistence of neutrophils (Pelletier et al., 2010; Lewkowicz et al., 2013). It was recently reported that Treg are increased when asthmatic horses are challenged with moldy hay (Henriquez et al., 2014), suggesting that these cells may be upregulated in equine asthma.

Glucocorticoids (GC) improve the clinical signs and airway obstruction in severe asthmatic horses without resolving the airway neutrophilia when the offending antigen exposure is maintained (Lavoie et al., 2002; Lavoie et al., 2006; Leclerc et al., 2011). Treg are among the targets of GC (D'Adamo et al., 1997; Ayroldi et al., 2001; Karagiannidis et al., 2004; Cannarile et al., 2006; Braitch et al., 2009) and it has been suggested that they have a stimulatory effect on these cells (Dao Nguyen and Robinson, 2004; Karagiannidis et al., 2004). However, it is unclear how Treg respond to GC in disease processes and whether they modulate the interactions between Treg and neutrophils (Ayroldi et al., 2001; Karagiannidis et al., 2004; Braitch et al., 2009; Yuksek et al., 2011; Olsen et al., 2015). Thus, in this study, we evaluated the effects of GC on pulmonary Treg of asthmatic horses and in healthy controls kept in the same environment. Based on previous works (Karagiannidis et al., 2004; Lewkowicz et al., 2005; Kearley et al., 2008), we hypothesized that 1) horses with severe asthma display a decreased population of pulmonary Treg when compared to controls and 2) that GC would lead to an increased Treg cell population in asthmatic horses.

2. Materials & Methods

2.1. Animals

Horses were part of a larger study evaluating the effects of glucocorticoids in equine asthma, and the animals, experimental protocol, physiological and inflammatory features have been reported previously (Vargas et al., 2017). In brief, 6 asthmatic horses and 6 age-matched controls were antigen-exposed by being stabled and fed hay for 1 month, then treated with dexamethasone (Dominion Veterinary Laboratories Ltd, MB, CA) at a dosage of 0.06 mg/kg once daily for 2 weeks. Lung function was measured in unsedated standing horses, using a pneumotachograph attached to a mask and an esophageal balloon catheter as previously described (Jean et al., 1999). Bronchoalveolar lavage fluids (BALF) were collected as previously described (Lavoie et al., 2001) before (Baseline), and after 1 week and 2 weeks of dexamethasone treatment. Cytocentrifuge preparations of BALF were stained with a modified Wright–Giemsa solution (Kwik-Diff, Fisher Scientific, Waltham, MA, USA). Differential cell counts were obtained from 400 cells. BALF were then centrifuged at 1600 rpm at 4 °C for 5 min and cells were resuspended in PBS 1X and further analyzed with flow cytometry.

All experimental procedures were performed in accordance with the Canadian Council for Animal Care guidelines and were approved by the Animal Care Committee for the Faculty of Veterinary Medicine of the University of Montreal (deontology Rech-1716).

2.2. Flow cytometry

Total BALF cells were studied by flow cytometry using Treg surface markers CD4 and FoxP3. Cells (3×10^6 cells) were fixed in paraformaldehyde 2% and washed three times in PBS 1X and incubated 10 min with PBS containing 0.1% Triton X-100 (Sigma-Aldrich, St-Louis, MO, USA). Cells were then stained for 30 min with anti-CD4 (Monoclonal Antibody Center, Washington State University, WA, USA; dilution 1/10), and anti-FoxP3-PE (Cedarlane, Burlington, ON, CA; dilution 1/10). All incubation steps were performed at 4 °C. Cells were then washed 3 times in PBS 1X and incubated 30 min in the dark with Alexa488-conjugated anti-IgG antibodies (Thermo Fisher Scientific, Waltham, MA, USA; dilution 1/500). Cells were washed twice and resuspended in 500 μ l PBS 1X before flow cytometry acquisition of 10 000 events and analysis using BD Accuri C6 software and instrument (BD Bioscience, San Jose, CA, USA). Isotype-matched control antibodies (rat IgG2a-PE and mouse IgG1; Vector Laboratories, Burlington, ON, CA; Miltenyi Biotec Auburn, CA, USA and AbD Serotec, Raleigh, NC, USA, respectively) were used as negative controls. Pulmonary lymphocytes were gated using forward scatter and side scatter profiles (FSC and SSC parameters, excluding cell debris, neutrophils and macrophages). CD4+ cells were then gated and FoxP3 expression was quantified against CD4+ gated cells regarding its control isotype. Signals greater than those of the isotype-matched controls were considered positive, and degree of staining was evaluated as the mean percentage of positive cells (Fig. 1).

2.3. Statistical analysis

Data were statistically evaluated using a repeated measure 2-way ANOVA, with time as within-subjects factor and treatment as between subject factor. Post-hoc analyses were performed using Dunnett tests and the Fisher's LSD tests, to compare treatment values to baseline within each group, or values between groups at each time point, respectively (GraphPad Prism 7.0c software). A p-value of 0.05 was considered significant and all results were expressed as mean $\pm$ standard error of the means (SEM).

3. Results and discussion

In this study, we investigated the Treg response to GC in the airways of horses with severe asthma and healthy controls. As expected, antigen exposure induced an airflow limitation in affected horses with increased transpulmonary pressure values ($p < 0.001$), whereas control horses maintained a normal lung function (Fig. 2A). As the transcription factor Foxp3 was shown to play an essential role in establishing a functional regulatory T cell lineage (Fontenot et al., 2003; Hori et al., 2003), we evaluated the proportion of pulmonary CD4+ lymphocytes expressing this marker. We observed that exacerbation of severe equine asthma was not associated with a significantly increased Treg cell population when compared to controls. These results at first sight contrast with the recent report of an increased in Treg in the airways of asthmatic horses after antigen challenge (Henriquez et al., 2014). However, the results of the latter study are difficult to compare to ours, as the Treg response to an acute challenge was previously investigated and it lacked a control group, while our study evaluated the Treg population in the airways after a chronic antigen exposition (> 3 weeks) in healthy and asthmatic horses kept in the same environment. Also, this difference may have been due to our sample size as a power calculation showed that 14 horses in each group would be required to demonstrate such an increase of pulmonary Treg cells at the baseline.

The Treg response to GC was different in the 2 groups of horses, as it was significantly increased with treatments in asthmatic horses ($p = 0.0005$), while the number of these cells were unaffected by therapy in controls ($p = 0.65$; Fig. 2B). GC treatment significantly increased pulmonary Treg cells value only after 2 weeks of treatment in




Fig. 1. Flow cytometry.

Flow cytometry plots of the gating strategy and the intensity of the FoxP3 staining in bronchoalveolar lavage (BAL) cells. A) Pulmonary lymphocytes were gated using forward scatter (FSC-A) and side scatter (SSC-A) profiles, excluding cell debris, neutrophils and macrophages. B) Staining for FoxP3 isotype control in the lymphocytes population and C) in the gated CD4+ lymphocytes population. D) Representative plot of the proportion of activated cells. Percentage of cells co-expressing CD4 and FOXP3 are reported in the upper-right quadrant of the plot. Data were acquired on BD Accuri C6. FL1-A = Intensity (Area) in the FL1 channel (green). FL2-A = Intensity (Area) in the FL2 channel (orange).

asthmatic group ($p > 0.6$ in controls) while the improvement of P_L values was already present after 1 week ($p = 0.0001$, and $p = 0.0001$ after 2 weeks). This delayed Treg response to GC compared to the improved lung function in asthmatic horses, suggests that these cells, when within the airway lumen, are unlikely to directly contribute to these early changes. It would be of interest in further studies to investigate the effects of GC on the Treg population present within the airway wall of asthmatic horses.

The effects of GC on the various blood cell populations are diverse and often conflicting (Goulding et al., 1990; D'Acquisto et al., 2008). It was therefore difficult to predict how these drugs would affect pulmonary Treg, especially considering their possible interactions with other lung cell types including other T cells subtypes and neutrophils. We first determined that GC had little effect on Treg in a healthy lung. This finding is in agreement with those of Sbiera and al. who showed that GC does not induce an increase of circulating Treg cells in naive mice or in healthy human subjects (Sbiera et al., 2011). To the contrary, a 2-week administration of GC was associated with an increased Treg in the lungs of asthmatic horses. Both of these results differ from previous reports suggesting that by promoting T cell apoptosis, GC would rather decrease the pulmonary Treg population (Iwata et al., 1991; Olsen et al., 2015). As these studies have been conducted respectively in murine model of allergen induced asthma and *in vitro* on murine thymocytes, these conclusions may not be applicable to naturally occurring conditions such as severe equine asthma. Ours results are however in agreement with the findings that GC inhibits Treg cell apoptosis (D'Adamio et al., 1997; Ayroldi et al., 2001) by direct binding to glucocorticoid-induced leucine zipper (GILZ), thereby preventing activity of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB)

(D'Adamio et al., 1997; Ayroldi et al., 2001). As NFκB activity is not inhibited by GC in bronchial cells of asthmatic horses (Couetil et al., 2006), our results supports the hypothesis that either GC acts on Treg via an NFκB independent pathway in the lungs or, more likely, that the effect of GC on NFκB is hidden by the persistent NFκB activity resulting from the continuous antigen exposure (Hohmann et al., 1991; Bureau et al., 2000). Our study also supports previous works in which Treg population was increased in human asthmatic lungs and with corticosteroids administration (Karagiannidis et al., 2004; Smyth et al., 2010; Thunberg et al., 2010). Moreover, these results might reflect an inability among Treg to suppress Th2 responses in asthmatic lungs, despite the quantitative changes.

The airways neutrophilia was unchanged by GC in either groups of horses in the present study, as already reported (Vargas et al., 2017). This finding is in agreement with previous reports using the same chronic natural challenge (Lavoie et al., 2002; Lavoie et al., 2006; Leclerc et al., 2011). GC promote survival of neutrophils and delay their clearance in the lung (Cox, 1995; Smoak and Cidlowski, 2004; Hirsch et al., 2012; Wang et al., 2016), which may contribute to their persistence in the asthmatic lungs. The pro-inflammatory cytokines release by sustaining neutrophilic population combined with a possible upregulation of FOXP3 by GC (Karagiannidis et al., 2004) might promote the local recruitment of Treg and increase their activation and survival. It has been shown that TGF-β may contribute to the recruitment of neutrophils and to the induction of FOXP3 in CD4+ lymphocytes (Chen et al., 2003; Fu et al., 2004). While total TGF-β concentration was not increased in BALF from asthmatic horses in a previous study, its contribution to the Treg recruitment in the airway of asthmatic horses cannot be ruled-out as active TGF-β₁ has not yet been investigated




Fig. 2. Pulmonary function and modulation of Treg by GC in the asthmatic's lung.

A) Maximal differences in transpleural pressure (ΔP_L) of asthmatic ($n = 6$) and healthy ($n = 6$) horses before (Baseline) and after treatment with dexamethasone (1 week and 2 weeks) (0.06 mg/kg once daily). Bars represent means $\pm$ SEM. B) Effect of antigenic challenge and GC treatment on percentage of Treg cell population. Percentage of CD4⁺ FOXP3⁺ Treg cells assessed by flow cytometry in BALF from asthmatic ($n = 6$) and healthy ($n = 6$) horses before (Baseline) and after treatment with dexamethasone (1 week and 2 weeks, 0.06 mg/kg once daily). Bars represent means $\pm$ SEM.

(Desjardins et al., 2004). Lastly, Treg can also contribute to the persistent airway neutrophilic inflammation during GC treatments, as they were shown to be a potential source of IL-8, a potent chemoattractant for neutrophils (Himmel et al., 2011; Langhans et al., 2013).

Taken together, results of the present study suggest a multifaceted and complex network of interactions between Treg cell population, neutrophil and GC. Our results support the need for further investigations of the triggering factors and the pathways involved in the pulmonary Treg recruitment to the asthmatic lung with GC treatments.

Conflict of interest statement

The authors declare no conflict of interest.

This study was supported by the NSERC (#RGPIN-2014-06-198).

Acknowledgments

The authors would like to thank Dr Eliane Marti for her technical advice related to this work.

References

- Ainsworth, D.M., Wagner, B., Franchini, M., Grunig, G., Erb, H.N., Tan, J.Y., 2006. Time-dependent alterations in gene expression of interleukin-8 in the bronchial epithelium of horses with recurrent airway obstruction. *Am. J. Vet. Res.* 67 (4), 669–677.
- Ayrolidi, E., Migliorati, G., Bruscoli, S., Marchetti, C., Zollo, O., Cannarile, L., D'Adamio, F., Riccardi, C., 2001. Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappaB. *Blood* 98 (3), 743–753.
- Braith, M., Hari Krishnan, S., Robins, R.A., Nichols, C., Fahey, A.J., Showe, L., Constantinescu, C.S., 2009. Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis. *Acta Neurol. Scand.* 119 (4), 239–245.
- Broide, D.H., Firestein, G.S., 1991. Endobronchial allergen challenge in asthma. Demonstration of cellular source of granulocyte macrophage colony-stimulating factor by in situ hybridization. *J. Clin. Invest.* 88 (3), 1048–1053.
- Bureau, F., Delhalle, S., Bonizzi, G., Fievez, L., Dogne, S., Kirschvink, N., Vanderplasschen, A., Merville, M.P., Bours, V., Lekeux, P., 2000. Mechanisms of persistent NF-kappa B activity in the bronchi of an animal model of asthma. *J. Immunol.* 165 (10), 5822–5830.
- Cannarile, L., Fallarino, F., Agostini, M., Cuzzocrea, S., Mazzon, E., Vacca, C., Genovese, T., Migliorati, G., Ayrolidi, E., Riccardi, C., 2006. Increased GILZ expression in transgenic mice up-regulates Th-2 lymphokines. *Blood* 107 (3), 1039–1047.
- Chen, W., Jin, W., Hardegen, N., Lei, K.J., Li, L., Marinos, N., McGrady, G., Wahl, S.M., 2003. Conversion of peripheral CD4⁺ CD25⁺ naive T cells to CD4⁺ CD25⁺ regulatory T cells by TGF-beta induction of transcription factor Foxp3. *J. Exp. Med.* 198 (12), 1875–1886.
- Choy, D.F., Hart, K.M., Borthwick, L.A., Shikotra, A., Nagarkar, D.R., Siddiqui, S., Jia, G., Ohri, C.M., Doran, E., Vannella, K.M., Butler, C.A., Hargadon, B., Sciurba, J.C., Gieseck, R.L., Thompson, R.W., White, S., Abbas, A.R., Jackman, J., Wu, L.C., Egen, J.G., Heaney, L.G., Ramalingam, T.R., Aron, J.R., Wynn, T.A., Bradding, P., 2015. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. *Sci. Transl. Med.* 7 (301), 301ra129.
- Couetil, L.L., Art, T., de Moffarts, B., Becker, M., Melotte, D., Jaspard, F., Bureau, F., Lekeux, P., 2006. Effect of beclomethasone dipropionate and dexamethasone isonicotinate on lung function, bronchoalveolar lavage fluid cytology, and transcription factor expression in airways of horses with recurrent airway obstruction. *J. Vet. Intern. Med.* 20 (2), 399–406.
- Cox, G., 1995. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. *J. Immunol.* 154 (9), 4719–4725.
- D'Acquisto, F., Paschalidis, N., Raza, K., Buckley, C.D., Flower, R.J., Perretti, M., 2008. Glucocorticoid treatment inhibits annexin-1 expression in rheumatoid arthritis CD4⁺ T cells. *Rheumatology (Oxford)* 47 (5), 636–639.
- D'Adamio, F., Zollo, O., Moraca, R., Ayrolidi, E., Bruscoli, S., Bartoli, A., Cannarile, L., Migliorati, G., Riccardi, C., 1997. A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. *Immunity* 7 (6), 803–812.
- Dao Nguyen, X., Robinson, D.S., 2004. Fluticasone propionate increases CD4CD25 T regulatory cell suppression of allergen-stimulated CD4CD25 T cells by an IL-10-dependent mechanism. *J. Allergy Clin. Immunol.* 114 (2), 296–301.
- Debrue, M., Hamilton, E., Joubert, P., Lajoie-Kadoch, S., Lavoie, J.P., 2005. Chronic exacerbation of equine heaves is associated with an increased expression of interleukin-17 mRNA in bronchoalveolar lavage cells. *Vet. Immunol. Immunopathol.* 105 (1–2), 25–31.
- Desjardins, I., Theoret, C., Joubert, P., Wagner, B., Lavoie, J.P., 2004. Comparison of TGF-beta 1 concentrations in bronchoalveolar fluid of horses affected with heaves and of normal controls. *Vet. Immunol. Immunopathol.* 101 (3–4), 133–141.
- Elfman, L., Riihimäki, M., Pringle, J., Walinder, R., 2009. Influence of horse stable environment on human airways. *J. Occup. Med. Toxicol.* 4, 10.
- Fontenot, J.D., Gavin, M.A., Rudensky, A.Y., 2003. Foxp3 programs the development and function of CD4⁺ CD25⁺ regulatory T cells. *Nat. Immunol.* 4 (4), 330–336.
- Fu, S., Zhang, N., Yopp, A.C., Chen, D., Mao, M., Chen, D., Zhang, H., Ding, Y., Bromberg, J.S., 2004. TGF-beta induces Foxp3⁺ T-regulatory cells from CD4⁺ CD25⁺ precursors. *Am. J. Transplant.* 4 (10), 1614–1627.
- Goulding, N.J., Godolphin, J.L., Sampson, M.B., Maddison, P.J., Flower, R.J., 1990. Hydrocortisone induces lipocortin 1 production by peripheral blood mononuclear cells in vivo in man. *Biochem. Soc. Trans.* 18 (2), 306–307.
- Henriquez, C., Perez, B., Morales, N., Sarmiento, J., Carrasco, C., Moran, G., Folch, H., 2014. Participation of T regulatory cells in equine recurrent airway obstruction. *Vet. Immunol. Immunopathol.* 158 (3–4), 128–134.
- Himmel, M.E., Crome, S.Q., Ivson, S., Piccirillo, C., Steiner, T.S., Levings, M.K., 2011. Human CD4⁺ FOXP3⁺ regulatory T cells produce CXCL8 and recruit neutrophils. *Eur. J. Immunol.* 41 (2), 306–312.
- Hirsch, G., Lavoie-Lamoureux, A., Beauchamp, G., Lavoie, J.P., 2012. Neutrophils are not less sensitive than other blood leukocytes to the genomic effects of glucocorticoids. *PLoS One* 7 (9), e44606.
- Hohmann, H.P., Remy, R., Scheidereit, C., van Loon, A.P., 1991. Maintenance of NF-kappa B activity is dependent on protein synthesis and the continuous presence of external stimuli. *Mol. Cell. Biol.* 11 (1), 259–266.
- Hori, S., Nomura, T., Sakaguchi, S., 2003. Control of regulatory T cell development by the

- transcription factor Foxp3. *Science* 299 (5609), 1057–1061.
- Ivester, K.M., Couetil, L.L., Zimmerman, N.J., 2014. Investigating the link between particulate exposure and airway inflammation in the horse. *J. Vet. Intern. Med.* 28 (6), 1653–1665.
- Iwata, M., Hanaoka, S., Sato, K., 1991. Rescue of thymocytes and T cell hybridomas from glucocorticoid-induced apoptosis by stimulation via the T cell receptor/CD3 complex: a possible in vitro model for positive selection of the T cell repertoire. *Eur. J. Immunol.* 21 (3), 643–648.
- Jean, D., Vrins, A., Lavoie, J.P., 1999. Monthly, daily, and circadian variations of measurements of pulmonary mechanics in horses with chronic obstructive pulmonary disease. *Am. J. Vet. Res.* 60 (11), 1341–1346.
- Karagiannis, C., Akdis, M., Holopainen, P., Woolley, N.J., Hense, G., Ruckert, B., Mantel, P.Y., Menz, G., Akdis, C.A., Blaser, K., Schmidt-Weber, C.B., 2004. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. *J. Allergy Clin. Immunol.* 114 (6), 1425–1433.
- Kearley, J., Barker, J.E., Robinson, D.S., Lloyd, C.M., 2005. Resolution of airway inflammation and hyperactivity after in vivo transfer of CD4 + CD25 + regulatory T cells is interleukin 10 dependent. *J. Exp. Med.* 202 (11), 1539–1547.
- Kearley, J., Robinson, D.S., Lloyd, C.M., 2008. CD4 + CD25 + regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling. *J. Allergy Clin. Immunol.* 122 (3), 617–624 (e616).
- Langhans, B., Kramer, B., Louis, M., Nischalke, H.D., Huneburg, R., Staratschek-Jox, A., Odenthal, M., Manekeller, S., Schepke, M., Kalf, J., Fischer, H.P., Schultze, J.L., Spengler, U., 2013. Intrahepatic IL-8 producing Foxp3(+)CD4(+) regulatory T cells and fibrogenesis in chronic hepatitis C. *J. Hepatol.* 59 (2), 229–235.
- Lavoie, J.P., Maghni, K., Desnoyers, M., Taha, R., Martin, J.G., Hamid, Q.A., 2001. Neutrophilic airway inflammation in horses with heaves is characterized by a Th2-type cytokine profile. *Am. J. Respir. Crit. Care Med.* 164 (8 Pt 1), 1410–1413.
- Lavoie, J.P., Leguillette, R., Pasloske, K., Charette, L., Sawyer, N., Guay, D., Murphy, T., Hickey, G.J., 2002. Comparison of effects of dexamethasone and the leukotriene D4 receptor antagonist L-708,738 on lung function and airway cytologic findings in horses with recurrent airway obstruction. *Am. J. Vet. Res.* 63 (4), 579–585.
- Lavoie, J.P., Pasloske, K., Joubert, P., Cordeau, M.E., Mancini, J., Girard, Y., Friesen, R.W., Frenette, R., Blouin, M., Young, R.N., Hickey, G., 2006. Lack of clinical efficacy of a phosphodiesterase-4 inhibitor for treatment of heaves in horses. *J. Vet. Intern. Med.* 20 (1), 175–181.
- Leclerc, M., Lavoie-Lamoureux, A., Lavoie, J.P., 2011. Heaves, an asthma-like disease of horses. *Respirology* 16 (7), 1027–1046.
- Lewkowicz, I.P., Herman, N.S., Schleifer, K.W., Dance, M.P., Chen, B.L., Dienger, K.M., Sproles, A.A., Shah, J.S., Kohl, J., Belkaid, Y., Wills-Karp, M., 2005. CD4 + CD25 + T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. *J. Exp. Med.* 202 (11), 1549–1561.
- Lewkowicz, N., Klink, M., Mycko, M.P., Lewkowicz, P., 2013. Neutrophil-CD4 + CD25 + T regulatory cell interactions: a possible new mechanism of infectious tolerance. *Immunobiology* 218 (4), 455–464.
- Lloyd, C.M., Hawrylowicz, C.M., 2009. Regulatory T cells in asthma. *Immunity* 31 (3), 438–449.
- MacDonald, K.G., Dawson, N.A., Huang, Q., Dunne, J.V., Levings, M.K., Broady, R., 2015. Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis. *J. Allergy Clin. Immunol.* e949.
- Olsen, P.C., Kitoko, J.Z., Ferreira, T.P., de-Azevedo, C.T., Arantes, A.C., Martins Mu, A., 2015. Glucocorticoids decrease Treg cell numbers in lungs of allergic mice. *Eur. J. Pharmacol.* 747, 52–58.
- Pelletier, M., Maggi, L., Micheletti, A., Lazzeri, E., Tamassia, N., Costantini, C., Cosmi, L., Lunardi, C., Annunziato, F., Romagnani, S., Cassatella, M.A., 2010. Evidence for a cross-talk between human neutrophils and Th17 cells. *Blood* 115 (2), 335–343.
- Riihimäki, M., Raine, A., Elfman, L., Pringle, J., 2008. Markers of respiratory inflammation in horses in relation to seasonal changes in air quality in a conventional racing stable. *Can. J. Vet. Res.* 72 (5), 432–439.
- Robinson, D.S., Tsicopoulos, A., Meng, Q., Durham, S., Kay, A.B., Hamid, Q., 1996. Increased interleukin-10 messenger RNA expression in atopic allergy and asthma. *Am. J. Respir. Cell Mol. Biol.* 14 (2), 113–117.
- Robinson, D.S., Larche, M., Durham, S.R., 2004. Tregs and allergic disease. *J. Clin. Invest.* 114 (10), 1389–1397.
- Sbiera, S., Dexeit, T., Reichardt, S.D., Michel, K.D., van den Brandt, J., Schmall, S., Kraus, L., Beyer, M., Mlynski, R., Wortmann, S., Allolio, B., Reichardt, H.M., Fassnacht, M., 2011. Influence of short-term glucocorticoid therapy on regulatory T cells in vivo. *PLoS One* 6 (9), e24345.
- Sehrawat, S., Rouse, B.T., 2017. Interplay of regulatory t cell and Th17Cells during infectious diseases in humans and animals. *Front. Immunol.* 8, 341.
- Setlakwe, E.L., Lemos, K.R., Lavoie-Lamoureux, A., Duguay, J.D., Lavoie, J.P., 2014. Airway collagen and elastic fiber content correlates with lung function in equine heaves. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 307 (3), L252–260.
- Smoak, K.A., Cidlowski, J.A., 2004. Mechanisms of glucocorticoid receptor signaling during inflammation. *Mech. Ageing Dev.* 125 (10–11), 697–706.
- Smyth, L.J., Eustace, A., Kolsum, U., Blaikely, J., Singh, D., 2010. Increased airway T regulatory cells in asthmatic subjects. *Chest* 138 (4), 905–912.
- Thunberg, S., Gafvelin, G., Nord, M., Gronneberg, R., Grunewald, J., Eklund, A., van Hage, M., 2010. Allergen provocation increases TH2-cytokines and FOXP3 expression in the asthmatic lung. *Allergy* 65 (3), 311–318.
- Tremblay, G.M., Ferland, C., Lapointe, J.M., Vrins, A., Lavoie, J.P., Cormier, Y., 1993. Effect of stabling on bronchoalveolar cells obtained from normal and COPD horses. *Equine Vet. J.* 25 (3), 194–197.
- Vargas, A., Boivin, R., Cano, P., Murcia, Y., Bazin, I., Lavoie, J.P., 2017. Neutrophil extracellular traps are downregulated by glucocorticosteroids in lungs in an equine model of asthma. *Respir. Res.* 18 (1), 207.
- Voo, K.S., Wang, Y.H., Santori, F.R., Boggiano, C., Wang, Y.H., Arima, K., Bover, L., Hanabuchi, S., Khalili, J., Marinova, E., Zheng, B., Littman, D.R., Liu, Y.J., 2009. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. *Proc. Natl. Acad. Sci. U. S. A.* 106 (12), 4793–4798.
- Wang, M., Gao, P., Wu, X., Chen, Y., Feng, Y., Yang, Q., Xu, Y., Zhao, J., Xie, J., 2016. Impaired anti-inflammatory action of glucocorticoid in neutrophil from patients with steroid-resistant asthma. *Respir. Res.* 17 (1), 153.
- Whittaker, A.G., Hughes, K.J., Parkin, T.D., Love, S., 2009. Concentrations of dust and endotoxin in equine stabling. *Vet. Rec.* 165 (10), 293–295.
- Yukse, M., Erol, F., Guloglu, D., Dogu, F., Elhan, A.H., Babacan, E., Ikinciogullari, A., 2011. Regulatory T cell levels in children with asthma. *Turk. J. Pediatr.* 53 (5), 532–536.